Harleysville Financial Corporation Announces Regular Cash Dividend and Second Quarter Earnings for Fiscal Year 2025
Net income for the second quarter was $2,130,000 or $.59 per diluted share compared to $2,112,000 or $.58 per diluted share for the same quarter last year.
Net income for the six months ended March 31, 2025 amounted to $4,136,000 or $1.14 per diluted share compared to $4,622,000 or $1.27 per diluted share for the same six-month period a year ago.
Brendan J. McGill, President, and Chief Executive Officer of the Company, stated, "Despite the volatility and uncertainty in the markets, the Company has achieved solid second quarter results. Our core banking business has continued to expand in fiscal 2025, net interest margin improved, loans and deposits have outperformed our projections, and our credit quality remains strong.
We will continue to maintain our prudent underwriting standards, investing in high credit quality assets, controlling our operating expenses, and practicing sound capital management. This together with our strong balance sheet will create a strong foundation for future results."
The Company's assets totaled $871.4 million compared to $847.4 million a year ago. Stockholders' tangible book value increased 4.5% to $24.40 per share from $23.34 a year ago.
Harleysville Financial Corporation is traded on the OTCQX market under the symbol HARL ( http://www.otcmarkets.com ) and is the holding company for Harleysville Bank. Established in 1915, Harleysville Bank is a Pennsylvania chartered and federally insured bank, headquartered in Harleysville, PA. The Bank operates from six full-service offices located in Montgomery County and one office located in Bucks County, Pennsylvania.
This presentation may contain forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995). Actual results may differ materially from the results discussed in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, general economic conditions, changes in interest rates, deposit flows, loan demand, real estate values and competition; changes in accounting principles, policies, or guidelines; changes in legislation or regulation; and other economic; competitive, governmental, regulatory, and technological factors affecting the Company's operations, pricing, products, and services.
Harleysville Financial Corporation
Selected Consolidated Financial Data as of March 31, 2025
(Dollars in thousands except per share data)
Year-To-Date
(Unaudited)
Six Months Ended:
Three Months Ended:
Selected Consolidated Earnings Data
Mar 31,2025
Mar 31,2024
Mar 31,2025
Dec 31,2024
Sep 30,2024
June 30,2024
Mar 31,2024
Total interest income
$
19,557
$
18,444
$
9,745
$
9,812
$
9,797
$
9,555
$
9,268
Total interest expense
6,887
5,536
3,274
3,613
3,681
3,261
2,984
Net Interest Income
12,670
12,908
6,471
6,199
6,116
6,294
6,284
Provision for loan losses
120
12
(28
)
148
46
13
4
Net Interest Income after Provision for Loan Losses
12,550
12,896
6,499
6,051
6,070
6,281
6,280
Bank owned life insurance
208
202
103
105
102
99
100
Other income
1,126
1,066
572
554
572
550
486
Total other expenses
8,478
8,081
4,434
4,044
4,161
4,228
4,110
Income before income taxes
5,406
6,083
2,740
2,666
2,583
2,702
2,756
Income tax expense
1,270
1,461
610
660
532
516
644
Net Income
$
4,136
$
4,622
$
2,130
$
2,006
$
2,051
$
2,186
$
2,112
Per Common Share Data
Basic earnings
$
1.14
$
1.27
$
0.59
$
0.55
$
0.56
$
0.60
$
0.58
Diluted earnings
$
1.14
$
1.27
$
0.59
$
0.55
$
0.56
$
0.60
$
0.58
Dividends
$
0.64
$
0.61
$
0.33
$
0.31
$
0.31
$
0.31
$
0.31
Special Dividend
$
-
$
1.20
$
-
$
-
$
-
$
-
$
-
Tangible book value
$
24.40
$
23.34
$
24.40
$
24.13
$
23.83
$
23.65
$
23.34
Shares outstanding
3,605,824
3,635,367
3,605,824
3,628,170
3,637,748
3,626,559
3,635,367
Average shares outstanding - basic
3,628,464
3,644,094
3,624,490
3,634,394
3,636,212
3,632,261
3,644,446
Average shares outstanding - diluted
3,635,410
3,652,806
3,631,337
3,641,435
3,643,915
3,640,387
3,653,117
(Unaudited)
Six Months Ended:
Three Months Ended:
Other Selected Consolidated Data
Mar 31,2025
Mar 31,2024
Mar 31,2025
Dec 31,2024
Sep 30,2024
June 30,2024
Mar 31,2024
Return on average assets
0.96
%
1.09
%
0.99
%
0.93
%
0.95
%
1.02
%
0.99
%
Return on average equity
9.45
%
10.91
%
9.66
%
9.24
%
9.53
%
10.28
%
10.04
%
Net interest rate spread
2.55
%
2.73
%
2.63
%
2.47
%
2.42
%
2.58
%
2.62
%
Net yield on interest earning assets
3.01
%
3.11
%
3.07
%
2.95
%
2.90
%
3.01
%
3.02
%
Operating expenses to average assets
1.97
%
1.90
%
2.06
%
1.88
%
1.93
%
1.98
%
1.93
%
Efficiency ratio
60.54
%
57.00
%
62.05
%
58.97
%
61.28
%
60.89
%
59.82
%
Ratio of non-performing loans to total
assets at end of period
0.14
%
0.21
%
0.14
%
0.18
%
0.17
%
0.20
%
0.21
%
Loan loss reserve to total loans, net
0.69
%
0.71
%
0.69
%
0.70
%
0.69
%
0.69
%
0.71
%
Stockholders' equity to assets
10.10
%
10.01
%
10.10
%
10.16
%
10.04
%
9.93
%
10.01
%
Selected Consolidated Financial Data
Mar 31,2025
Dec 31,2024
Sep 30,2024
June 30,2024
Mar 31,2024
Total assets
$
871,430
$
861,327
$
862,988
$
863,899
$
847,416
Cash & investment securities
13,577
14,198
16,525
22,892
20,853
Mortgage-backed securities
125,115
124,774
127,523
132,621
138,072
Total Investments
138,692
138,972
#
144,048
155,513
158,925
Consumer Loans receivable
341,850
341,175
340,618
335,802
325,483
Commercial Loans receivable
357,076
348,424
343,346
337,872
329,235
Loan loss reserve
(4,828
)
(4,854
)
(4,714
)
(4,668
)
(4,662
)
Total Loans receivable net
694,098
684,745
679,250
669,006
650,056
FHLB stock
3,874
3,909
5,501
5,366
4,813
Checking accounts
266,215
259,589
255,472
255,110
264,294
Savings accounts
214,159
206,369
208,491
223,101
229,208
Certificate of deposit accounts
216,918
224,273
201,424
180,007
166,664
Total Deposits
697,292
690,231
665,387
658,218
660,166
Advances
74,016
74,585
102,273
108,078
92,757
Total stockholders' equity
87,986
87,552
86,686
85,765
84,837
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416865498/en/
Contacts
FOR FURTHER INFORMATIONM. Shane MichalakSenior Vice President/CFO215-256-8828
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
John Marshall Bancorp extends share repurchase program
John Marshall Bancorp (JMSB),the parent holding company for John Marshall Bank, announced that its Board of Directors authorized the extension of the stock repurchase program through August 31, 2026, pursuant to which the Company is authorized to purchase up to 700,000 shares of the Company's outstanding common stock. To date, the Company has repurchased 93,103 shares, or $1.6M under the Stock Repurchase Program. The Stock Repurchase Program may be suspended, terminated, amended or modified by the Board at any time without prior notice at the Board's discretion. About John Marshall Bancorp, Inc. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Wire
5 hours ago
- Business Wire
EverGen Infrastructure Announces Dates for 2025 Second Quarter Financial Results and Conference Call
VANCOUVER, British Columbia--(BUSINESS WIRE)-- EverGen Infrastructure Corp. ('EverGen' or the 'Company') (TSXV: EVGN) (OTCQX: EVGIF), today announced plans to release its 2025 second quarter financial results on August 21, 2025, after market close. EverGen will hold a results and corporate update conference call at 11:00 a.m. eastern time on Friday, August 22, 2025, hosted by Chief Executive Officer, Chase Edgelow. Conference Call Details are as follows: Date: Time: 11:00 a.m. ET About EverGen Infrastructure Corp. EverGen, Canada's Renewable Natural Gas Infrastructure Platform, is combating climate change and helping communities contribute to a sustainable future. Headquartered on the West Coast of Canada, EverGen is an established independent renewable energy producer which acquires, develops, builds, owns and operates a portfolio of Renewable Natural Gas, waste to energy, and related infrastructure projects. EverGen is focused on Canada, with continued growth expected across other regions in North America and beyond. For more information about EverGen Infrastructure Corp. and our projects, please visit Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Business Wire
6 hours ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
